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TreatmentAbstract Background: Older women are more likely to be diagnosed with primary metastas-
ised breast cancer than their younger counterparts. Evolving treatment strategies of metastas-
ised breast cancer have resulted in improved survival in younger patients, but it remains
unclear if this improvement has occurred in older patients as well. The aim of this study
was to assess changes in treatment strategies over time in relation to overall and relative sur-
vival of older patients compared to younger patients with primary metastasised breast cancer.
Methods: All patients with a breast cancer diagnosis and distant metastases at ﬁrst presenta-
tion (stage IV), between 1990 and 2012, were selected from the Netherlands Cancer Registry.
Changes in treatment over time per age-group (<65 years, 65–75 years and >75 years)
were assessed using logistic regression. Overall survival over time was calculated using Cox
Regression Models and relative survival was assessed using the Ederer II method.
Results: Overall, 14,310 patients were included. Treatment strategies have strongly changed in
the past twenty years; especially the use of chemotherapy has increased (P < 0.001 in all age-
groups). Overall survival of patients <65 has signiﬁcantly improved (Hazard Ratio (HR) per
year 0.98, 95% Conﬁdence Interval (CI) 0.98–0.99, P < 0.001), but the survival of older
patients has not improved (HR 1.00, 95% CI 0.99–1.01, P = 0.86 for patients aged 65–75
and HR 1.00, 95% CI 1.00–1.01, P = 0.46 for patients aged >75). Similarly, relative survival
has improved in patients <65 but not in women aged 65–75 and >75.
Conclusion: Overall and relative survival of older patients with metastasised breast cancer at
ﬁrst presentation have not improved in recent years in contrast with the survival of younger
N.A. de Glas et al. / European Journal of Cancer 51 (2015) 310–316 311patients, despite increased treatment with chemotherapy for women of all ages. Future studies
should focus on stratiﬁcation models that can be used to predict which patients may beneﬁt
from speciﬁc treatment options.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Breast cancer is still the leading cause of cancer-
related mortality in women worldwide [1]. About 5–
10% of breast cancer patients present with distant
metastases at diagnosis [2]. In recent years, treatment
of metastatic breast cancer has evolved, especially due
to the development of new endocrine therapies, novel
chemotherapeutic regimens and targeted therapy includ-
ing trastuzumab [3,4]. Several studies have shown that
these improvements have led to an improvement of sur-
vival rates of metastasised breast cancer patients [3,5,6].
However, it is uncertain whether this improvement in
survival has occurred in older patients with metastasised
breast cancer as well. This is an important issue, as older
patients are more likely to be diagnosed with advanced
or metastasised breast cancer than their younger coun-
terparts [2,7].
Since older patients are generally underrepresented in
randomised clinical trials [8], current guidelines for
treatment of older patients with metastasised breast can-
cer are mostly based on studies that were performed in
younger populations [7,9]. In addition, older breast can-
cer patients who are included in clinical trials, have a
more favourable prognosis than the general older breast
cancer population [10]. It is well known that older breast
cancer patients comprise a heterogeneous group due to
large diﬀerences in comorbidity, functional status and
geriatric syndromes between patients [11–13]. This large
variation in phenotypes makes it diﬃcult to extrapolate
general guidelines to the individual older breast cancer
patients. By studying observational data, we can gain
better insight in outcomes after treatment of older breast
cancer patients with metastasised breast cancer in the
population.
The aim of this nationwide observational study was
to assess changes in treatment strategies over time, in
relation to overall and relative survival of older patients
compared to younger patients with primary metastas-
ised breast cancer.2. Methods
All patients with metastasised (stage IV) breast can-
cer at time of the initial diagnosis, who were diagnosed
between 1989 and 2012 were selected from the Nether-
lands Cancer Registry. The Netherlands Cancer Regis-
try registers data of all patients who are diagnosed
with cancer in the Netherlands. Patients are detectedthrough the central pathology database, after which
trained personnel obtain patient, tumour and treatment
characteristics from the patient charts. Follow-up status
is available through linkage with municipal population
registries, and was complete until December 31st, 2012.
Stage IV disease was deﬁned as pathological stage at
diagnosis according to the Tumour-Node-Metastasis
(TNM)-stage that was used in the year of diagnosis. If
pathological stage was missing, clinical stage was used.
Oestrogen-receptor (ER) status and Progesteron-recep-
tor (PR) status were available from the year 2005.
All patients were divided into three age-groups (<65,
65–75 and >75). Surgical treatment, axillary surgery,
radiotherapy, ﬁrst-line endocrine therapy and chemo-
therapy were available as binary variables since details
about the speciﬁc therapies were lacking. The most
extensive surgery and axillary surgery were used for
the analyses.2.1. Statistical analyses
All analyses were performed in IBM SPSS Statistics
version 20.0 and STATA version 12.0. All statistical
tests were two-sided, and a P-value smaller than 0.05
was considered as signiﬁcant. If data were missing,
patients were not excluded from the analyses, but ana-
lysed as a separate ‘unknown’ group within the same
variable.
First, we graphically depicted the proportion of
patients who received any of the speciﬁed treatments
(surgery, radiotherapy, endocrine therapy and chemo-
therapy) per age-group. Diﬀerences between groups
were assessed using Chi-square tests. Second, we
depicted all treatment strategies over time, and assessed
if the proportion of patients receiving speciﬁc treatments
signiﬁcantly changed over time using logistic regression
models with the treatment as the outcome and the year
of diagnosis as continuous variable.
Next, we calculated overall survival over time for all
age-groups using Cox Regression Models. These analy-
ses were additionally adjusted for age at diagnosis and
tumour characteristics (grade, morphology, hormone
receptor status and number of metastatic sites).
Finally, we assessed relative survival over time by cal-
culating the relative excess risk (RER) using the Ederer
II method. This method calculates the ratio of the
survival observed among cancer patients divided by
the survival of the corresponding general population
(‘expected survival’), matched by age, sex and year of
Fig. 1. Treatment per age-group.
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expected survival. Again, these analyses were adjusted
for age at diagnosis and relevant tumour characteristics
(grade, morphology, hormone receptor status and num-
ber of metastatic sites).
3. Results
Overall, 14,310 patients were included (7246 aged
<65 years, 3,259 patients between the ages of 65 and
75 and 3805 patients aged >75 years, Table 1). Younger
patients were more frequently diagnosed with tumours
of ductal morphology than older patients (54.0% of
patients aged <65, 46.9% of patients aged 65–75 and
46.1% of patients aged >75, P < 0.001). Younger
patients had more metastatic sites than older patients
(P < 0.001) and metastases were more often localised
in bone and liver in younger patients (34.5% of patients
aged <65 presented with bone metastases versus 31.8%
of patients >75, P < 0.001 while 20.8% of patients <65
presented with liver metastases versus 10.1% of patients
>75, P < 0.001).
Older patients received signiﬁcantly less surgical
treatment and radiotherapy for the primary tumour
(32.3% of patients aged <65, 23.1% of patients aged
65–75 and 16.7% of patients aged >75 received surgical






N % N %
Grade
I 326 (2.3) 157 (2.2)
II 1762 (12.3) 969 (13.3)
III 2988 (20.8) 1799 (24.8)
Unknown 9265 (64.6) 4343 (59.8)
Morphology
Ductal 7209 (50.3) 3925 (54.0)
Lobular 1887 (13.2) 910 (12.5)
Other 5245 (36.6) 2433 (33.5)
Oestrogen-receptor/progesteron-receptor (ER/PR) statusa
Negative 1077 (7.5) 637 (8.8)
Positive 4042 (28.2) 2117 (29.2)
Unknown 9191 (64.2) 4492 (62.0)
Metastases localisationb
Bone 4687 (32.7) 2505 (34.5)
Lung 1458 (10.2) 680 (9.4)
Liver 2270 (15.8) 1515 (20.8)
Other 2447 (17.1) 1177 (16.3)
Unknown 5262 (36.7) 2479 (34.1)
Number of metastatic sites
1 10,733 (74.8) 5232 (72.0)
2 2319 (16.2) 1252 (17.2)
3 or more 1289 (9.0) 784 (10.8)
a Available from the year 2006.
b More than one localisation possible.12.4% of patients aged 65–75 and 8.2% of patients aged
>75 received radiotherapy, P < 0.001). Furthermore,
older patients were more likely to receive endocrine
treatment and less likely to receive chemotherapy than
their younger counterparts (P < 0.001 for both treat-
ments, Fig. 1).
Treatment strategies of metastasised breast cancer
have strongly changed over time (Fig. 2). The propor-





N % N %
70 (2.1) 99 (2.6) <0.001
412 (12.6) 381 (10.0)
623 (19.1) 566 (14.9)
2157 (66.1) 2765 (72.6)
1529 (46.9) 1755 (46.1) <0.001
491 (15.1) 486 (12.8)
1242 (38.1) 1570 (41.2)
200 (6.1) 240 (6.3) <0.001
814 (25.0) 1111 (29.2)
2245 (68.9) 2454 (64.5)
970 (29.7) 1212 (31.8) <0.001
320 (9.8) 458 (12.0) <0.001
370 (11.3) 385 (10.1) <0.001
708 (18.6) 663 (17.4) 0.007
1310 (40.2) 1473 (38.7) <0.001
2489 (76.3) 3012 (79.0) <0.001
504 (15.5) 563 (14.8)
269 (8.2) 236 (6.2)
Fig. 2. Treatment modalities over time per age-group. All ﬁgures are presented as three-year moving means. P-values were calculated using logistic
regression, and represent p for trend for year of diagnosis.
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30.1% in 1995), but strongly decreased after 1998 in all
age-groups (30.1% in 1995 to 20.5% of patients in
2012 were surgically treated P for trend over the whole
time period (1990–2012) = 0.005). Also, use of radio-
therapy signiﬁcantly decreased in all age-groups between
1990 and 2012 (P for trend <0.001). In contrast, the use
of ﬁrst line endocrine treatment slightly increased in
patients aged <65, but decreased in patients aged 65–
75 and patients aged >75. Finally, the proportion of
patients receiving chemotherapy signiﬁcantly increased
in all age-groups (P for trend <0.001 for all age-groups).Fig. 3. Median overall survival over time per age-group. Data are presen
adjusted for age at diagnosis, oestrogen-receptor/progesteron-receptor (ERMedian overall survival was 1.78 years in patients
<65 years, inter quartile range (IQR) 0.72–3.47. In
patients aged 65–75, median survival was 1.34 years,
IQR 1.34–3.08, while median survival of patients >75
was 0.97 years, IQR 0.24–2.40 years. The overall sur-
vival of the whole cohort of patients has signiﬁcantly
improved in the past twenty years (multivariable
adjusted Hazard Ratio (HR) 0.99, 95% Conﬁdence
Interval (CI) 0.99–1.00, P < 0.001, Fig. 3). This survival
gain was fully explained by the improved survival of
younger patients (multivariable adjusted HR 0.98, 95%
CI 0.98–0.99 per year, P < 0.001), as the survival ofted as 3-year moving means. All presented Hazard Ratios (HRs) are
/PR) status, morphology, grade and number of metastatic sites.
Fig. 4. 5-Year relative survival over time per age-group. Data are presented as 3-year moving means. All presented Relative Excess Risks (RERs)
are adjusted for age at diagnosis, oestrogen-receptor/progesteron-receptor (ER/PR) status, morphology, grade and number of metastatic sites.
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iable adjusted HR 1.00, 95% CI 0.99–1.01 per year,
P = 0.86 for patients aged 65–75 and multivariable
adjusted HR 1.00, 95% CI 1.00–1.01 per year,
P = 0.46 for patients aged >75).
Similarly, relative survival has improved for the
whole cohort (multivariable adjusted RER 0.98, 95%
CI 0.98–0.99 per year, P < 0.001, Fig. 4). Again, this
improvement of relative survival was fully explained
by a survival gain in younger patients (multivariable
adjusted RER 0.98, 95% CI 0.97–0.99 per year,
P < 0.001 for patients <65 years). Relative survival did
not improve in patients older than 65 years (multivari-
able adjusted RER 1.00, 95% CI 0.99–1.01 per year,
P = 0.77 for patients aged 65–75 and multivariable
adjusted RER 1.01, 95% CI 1.00–1.02 per year,
P = 0.23 for patients aged 75 years and older).4. Discussion
This study shows that treatment strategies for both
older and younger patients with metastasised breast can-
cer have drastically changed in the past twenty years.
However, these changes have only resulted in improved
overall and relative survival rates in younger women
with metastasised breast cancer, while survival of older
patients with metastasised breast cancer has not
improved.
Around 80% of older women with breast cancer have
hormone-receptor positive disease [9], which explains
the high prescription rate of endocrine treatment in
older women in our data. In the early nineties, tamoxi-
fen was the ﬁrst line endocrine treatment. After 2002,
third generation aromatase inhibitors were incorporated
as ﬁrst line treatment of metastasised ER-positive breast
cancer in the Dutch national guideline [14], as they were
shown to be superior as compared to tamoxifen in post-
menopausal women with advanced breast cancer [15].
Of note, we observed almost no changes in the percent-
age of older women who received endocrine treatment,but it is likely that an increasing proportion of patients
was treated with aromatase inhibitors after 2002.
Also, we have shown that an increasing proportion of
patients over the age of 65 was treated with chemother-
apy in more recent years. Several chemotherapeutic reg-
imens have become available that are well tolerated by
older women such as capecitabine and liposomal doxo-
rubicin [9]. In older patients, monotherapy with chemo-
therapeutic drugs with low toxicity proﬁles is generally
preferred to combined chemotherapy regimens,
although strong evidence in older patients is lacking
[7,9]. In addition, treatment with bisphosphonates for
patients with bone metastases has been advised since
the late 1990s to all women with bone metastases [14],
but it is unlikely that this has attributed to changes in
survival rates, as no survival beneﬁt for treatment with
bisphosphonates has been proven in patients with
metastasised breast cancer [14,16].
Despite these evolving palliative treatments, we have
shown that survival of older patients with metastasised
breast cancer lacks behind compared to survival of
younger patients. These ﬁndings are in line with previ-
ous studies that were performed in patients with non-
metastasised breast cancer [17]. The increasing survival
gap may be explained by both undertreatment and over-
treatment of older patients. Possibly, there are patients
who would beneﬁt from palliative chemotherapy and
targeted therapy, but who do not receive it due to age
discrimination. On the other hand, frail elderly women
may suﬀer decreased survival due to unanticipated tox-
icity of chemotherapy or hormonal therapy.
An important consideration in treating older patients
with metastasised breast cancer, is to determine the
goals of treatment. In patients with metastasised breast
cancer, the main treatment goals should be to maintain
quality of life, to minimise disease symptoms and to pro-
long survival without causing toxicity of treatment
[7,9,18]. Balancing survival gain and toxicity is especially
challenging in older patients, since older breast cancer
patients are at increased risk of adverse outcomes of sur-
gical treatment, chemotherapy and endocrine therapy
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ciﬁc treatments [18]. A possible tool for this purpose
may be the geriatric assessment [18]. Several studies have
shown that a geriatric assessment can predict the risk of
early mortality as well as toxicity of treatments in the
adjuvant setting [22–24] and this might also apply to
palliative treatment of metastasised breast cancer. A
recent study by van de Water et al. suggested that treat-
ment of older patients, in an oncogeriatric care pro-
gramme may result in an improved overall survival of
older patients [25]. In this programme, treatment choices
were guided by a comprehensive geriatric assessment
[25], thereby improving individualised treatment. How-
ever, this study included only a small number of
patients, and it remains unclear if an improved selection
of older patients truly improves the clinical outcome of
older breast cancer patients.
Unfortunately, few studies have speciﬁcally investi-
gated breast cancer treatment in older patients, espe-
cially in metastasised breast cancer. Older patients are
generally underrepresented in clinical trials [7] and older
women who participate in trials tend to have more
favourable prognostic patient and tumour characteris-
tics than patients in the general population [8,10]. Con-
sequently, trial results cannot be extrapolated to the
general older breast cancer population. Furthermore,
currently ongoing trials rarely incorporate end-points
that are relevant for older patients such as functional
status or quality of life [26]. This is not diﬀerent for clin-
ical trials in patients with metastasised breast cancer.
Therefore, studying observational data will be essential
in order to improve our knowledge in the treatment of
older breast cancer patients in the near future. Recently,
we have initiated a prospective observational study in
metastasised older breast cancer patients. In this study,
we will perform a geriatric assessment at the time of
diagnosis, after which we will prospectively register
functional, cognitive and psychological decline as well
as quality of life of these patients.
4.1. Strengths and limitations
The main strength of this study is the large number of
included patients from the Netherlands Cancer Registry
with well-registered, quality assured data. Also, this
study provides new insights in the poor outcome of
older patients with metastasised breast cancer.
Of course, this study also has its limitations. Impor-
tantly, we were not able to incorporate speciﬁc patient
characteristics such as comorbidity in our analyses, as
these data are not registered in the Netherlands Cancer
Registry. Also, speciﬁc details of the prescribed thera-
pies were not available. In addition, the data of the
Netherlands Cancer Registry are gathered between six
months and one year after diagnosis of patients, and fol-
low-up is provided by linkage to municipal systems. This
means that mainly treatments that are prescribed as theﬁrst line of treatment are registered in the Netherlands
Cancer Registry, which may lead to an underestimation
of the proportion of patients who receive chemotherapy
and/or endocrine therapy. Finally, one could argue that
the fact that we did not assess breast cancer speciﬁc sur-
vival is a limitation of the study. However, by using rel-
ative survival, we believe that we have used a reasonable
alternative, as it has been shown that relative survival
can be used as a valid proxy for cancer speciﬁc survival
[27]. Furthermore, estimation of the cause of death is
especially diﬃcult in older patients [28], which makes
relative survival a more reliable end-point [27].
In conclusion, despite evolving treatment strategies,
overall and relative survival of older patients with
metastasised breast cancer have not improved in recent
years in contrast with the survival of younger patients,
thereby increasing the survival gap between young and
older patients with metastasised breast cancer. In order
to individualise care of older breast cancer patients with
metastasised breast cancer, future studies should focus
on stratiﬁcation methods that can be used to decide
which patients should receive certain treatments and
that can predict speciﬁc outcomes that are especially
of interest for older breast cancer patients, such as func-
tional status and quality of life.
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